Work

Capillary dried plasma microsampling: A novel approach for therapeutic drug monitoring of tyrosine kinase inhibitors in chronic myeloid leukemia patients by UPLC-MS/MS

Year: 2026

Type: article

Abstract: The individualized pharmacological treatment of Chronic Myeloid Leukemia (CML) with tyrosine kinase inhibitors (TKIs) has shown greater efficacy and safety when guided by plasma concentration monitoring. However, in Brazil, this strategy is not yet implemented for TKIs. In this context, alternative sampling methods, such as dried plasma spots (DPS), may improve the feasibility and accessibility of therapeutic drug monitoring. This study aimed to develop and validate a bioanalytical method for quantifying dasatinib, nilotinib, imatinib, and their metabolites in DPS using the HealthID® plasma separation device and UHPLC-MS/MS. The analytes were extracted from three 6 mm discs with 0.1% BSA and ethyl acetate:n-propanol (95:5, v/v). The Analysis was performed via UHPLC-MS/MS with positive electrospray ionization, using a C18 column and gradient elution with 0.1% formic acid in water and acetonitrile. The method was validated and applied to DPS samples from 51 CML patients. The analytical run time was 6 min, with linearity (r > 0.99), CVs between 3.33%-14.99%, and accuracy from 95.3% to 103.9%. Extraction yields ranged from 49% to 68%. The analytes were stable at room temperature in DPS for one month. Mean TKI concentrations in DPS represented 98.1-100.9% of plasma levels. These results support the potential of DPS as a viable strategy for TKI monitoring, offering logistical advantages and sample stability without refrigeration.

Source: Journal of Pharmaceutical and Biomedical Analysis

DOI: 10.1016/j.jpba.2026.117789